Curriculum Vitae Europass

Informazioni personali

Cognome Nome	**Federici Augusto Bramante**
Indirizzo	**via S. Orsola 3, 20123 Milano, Italia**
Telefoni	**02 3904 2365 – 02 5031 9895** **Mobile: 393 4676633**
Fax	**02 3820 0264 – 02 5031 9897**
E-mail	**augusto.federici@unimi.it**
Cittadinanza	Italiana
Data di nascita	16 Gennaio 1952
Sesso	maschile
Codice Fiscale	FDR GTB 52A16 F205W
Occupazione desiderata	Medico, Specialista in Ematologia, Medicina Interna, Oncologia
Settore professionale	Docente Universitario Malattie del Sangue, Professore Associato presso Università degli Studi di Milano

Esperienza professionale Dal 1977 (ad oggi)

Nome e indirizzo del datore di lavoro	Università degli Studi di Milano – Dipartimento di Oncologia ed Ematologia Oncologica (DIPO) via S. Sofia 11/6, 20122 Milano. Direttore Struttura Complessa di Ematologia e Medicina Trasfusionale, A.O. e Polo Universitario, Ospedale Luigi Sacco, ASST-FBF-SACCO via G.B. Grassi 74, 20154 Milano
Lavoro o posizione ricoperti	**2002-Pres.** Professore Associato Confermato di Malattie del Sangue (MED15) Università degli Studi di Milano **A.A. 2008-2009**: Direttore 2^ Scuola di Specializzazione in Ematologia, Università degli Studi di Milano **Dal 2008 al 2010**: Direttore Comitato Scientifico Centro Ricerche Angelo Bianchi Bonomi, Università degli Studi di Milano. **Dal 16 aprile 2009**: Direttore Struttura Complessa di Ematologia e Medicina Trasfusionale, AO. e Polo Universitario, Ospedale Luigi Sacco, via G.B. Grassi 74, 20154 Milano
Tipo di attività o settore	Diagnosi e trattamento dei pazienti con malattie del sangue benigne e maligne con particolare esperienza nei casi con problemi emorragici e trombosi.
Principali attività e responsabilità	Affidamento di incarico dirigenziale professionale di alta specializzazione con responsabilità organizzativa, presso U.O. Medicina Interna 2, IRCCS Fondazione Ospedale Maggiore di Milano. **Dal 16 aprile 2009**: Direttore UOC di Ematologia e Medicina Trasfusionale, A.O. e Polo Universitario, Ospedale Luigi Sacco, via G.B. Grassi 74, 20154 Milano **2017.** Abilitazione Scientifica Nazionale a Professore Ordinario per il Settore Concorsuale 06/D3 – Malattie del Sangue, Oncologia e Reumatologia.

Istruzione e formazione

Date

1989, Specializzazione in Oncologia, Università di Pavia (con lode)
1987, Idoneità Nazionale a Primario Ematologo
1985, Specializzazione in Medicina Interna, Università di Pavia
1982, Corsi semestrali in Biochimica delle Macromolecole, Università California San Diego (USA)
1980, Specializzazione in Ematologia Clinica e di Laboratorio, Università di Pavia (con lode)
1977, Laurea in Medicina, Università di Milano (con lode)
1971, Diploma di Maturità Classica, Liceo Giosuè Carducci, Milano.

Titolo della qualifica rilasciata

Dottore in Medicina e Chirurgia (1977), Specializzazioni in Ematologia Clinica e di Laboratorio (1980), Medicina Interna (1985), Oncologia (1989).

Principali tematiche/competenze professionali possedute

Esperto di malattie del sangue con particolare riguardo alle malattie emorragiche e trombosi congenite ed acquisite ed alle complicazioni emorragiche e trombosi nei tumori.

Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione

Membro del Comitato per la Standardizzazione dei difetti del VWF nella Società Internazionale per lo studio dell'emostasi e della trombosi (ISTH) - Studi sulla Malattia di von Willebrand (VWD). Co-Chair e Chairman del Sottocomitato sul VWF della ISTH; Membro Eletto del Comitato Direttivo della Società Italiana di Ematologia Sperimentale **(2006-2010)**; Membro del Comitato Scientifico sull'Emostasi dell'ASH, Società Americana di Ematologia **(2010-2016).**

Livello nella classificazione nazionale o internazionale

Esperto riconosciuto per le malattie emorragiche nell'ambito della Federazione Mondiale per l'Emofilia. Membro del Comitato Internazionale per VWD e delle malattie rare della coagulazione (RBD)

Capacità e competenze personali

Madrelingua

Italiano

Altre lingue

1) Inglese; 2) Francese

Autovalutazione *Livello europeo (*)*	Comprensione				Parlato				Scritto	
	Ascolto		Lettura		Interazione orale		Produzione orale			
Inglese	1	Ottimo		Ottimo		Ottimo		Ottimo		Buono
Francese	2	Ottimo		Ottimo		Ottimo		Ottimo		Buono

(*) Quadro comune europeo di riferimento per le lingue

Capacità e competenze sociali

Attività di organizzazione e coordinamento di gruppi di lavoro clinici.
Attività di organizzazione e coordinamento di gruppi di lavoro di ricerca.
Attività di insegnamento formale ed addestramento pratico agli studenti in Medicina, Biologia, Biotecnologie Mediche, Specializzandi in Ematologia

Capacità e competenze organizzative

Direzione Organizzativa di UOC di Ematologia e Medicina Trasfusionale, presso l'Ospedale Luigi Sacco di Milano, A.O. e Polo Universitario dal **16 aprile 2009.** Direttore UOS di Diagnosi e Trattamento dei difetti dell'emostasi e Dirigente professionale di alta specializzazione con responsabilità organizzativa, presso U.O. Medicina Interna 2, IRCCS Ospedale Maggiore di Milano, internazionalmente conosciuta. Organizzazione convegni medici e scientifici sulle malattie emorragiche e trombotiche. Project management di studi clinici sulle malattie emorragiche e trombotiche. Project Scientific Coordination and Management di Progetti Finanziati dalla Comunità Europea sulla malattia di von Willebrand; BIOMED99 (1999-2002); FRAMEWORK 5 (2003-2006). Progetti in collaborazione con Università degli USA: Registri su Acquired Defects of Hemostasis. Scientific Coordinator di un progetto internazionale intitolato: Type 3 Von Willebrand International Registries Inhibitor Prospective Study (2012-pres).

Capacità e competenze di ricerca e tecniche

1984-1988 Membro eletto del Comitato Esecutivo della Società Italiana per lo Studio dell'Emostasi e della Trombosi (SISET).

1985-1988 Grant di ricerca della NATO n.RG 85/0725, per la collaborazione con la Scripps Research Institute, La JOLLA, CA (Dr. T.S. Zimmerman).

1996-2000	Grant di ricerca dell'Istituto Superiore di Sanità Italiano come Responsabile del Progetto intitolato "Registro Nazionale di pazienti con Malattia di Willebrand (RENAWI) ed indicazioni all'uso dei concentrati.
1998-2006	Co-Chairman and Chairman (2004) del Sotto-Comitato sul VWF nell'ambito dei Comitati Scientifici per la Standardizzazione (SSC) della Società Internazionale Emostasi e Trombosi (ISTH).
2000-2005	Grant della Comunità Europea per il Progetto intitolato "Molecular and Clinical Markers of Diagnosis and Management of Type 1 Von Willebrand Disease".
2006-2010	Membro eletto del Comitato Esecutivo della Società Italiana di ematologia Sperimentale (SIES).
2008-2009	Direttore della Seconda Scuola di Specializzazione in Ematologia, Università di Milano.
2008-2010	Direttore del Comitato Scientifico della Fondazione A. B. BONOMI
2010-2015	Membro del Comitato Scientifico per l'Emostasi della Società Americana di Ematologia (ASH)
2012-pres	Coordinatore e poi Membro nominato del Gruppo di Lavoro sull'Emostasi e Trombosi del GIMEMA

Capacità e competenze informatiche	Utilizzo dei principali applicativi informatici
Capacità e competenze artistiche	Descrivere tali competenze e indicare dove sono state acquisite. (facoltativo, v. istruzioni)
Altre capacità e competenze	Descrivere tali competenze e indicare dove sono state acquisite. (facoltativo, v. istruzioni)
Patente	Indicare la(e) patente(i) di cui siete titolari precisandone la categoria. (facoltativo, v. istruzioni)
Ulteriori informazioni	Inserire qui ogni altra informazione utile, ad esempio persone di riferimento, referenze, ecc. (facoltativo, v. istruzioni)
Allegati	Enumerare gli allegati al CV. (facoltativo, v. istruzioni) **1. Elenco dei 201 lavori citati da Pub MED con Impact FACTOR > 850**

Si autorizza al trattamento dei dati personali

Firmato in data 28 Agosto 2019

Prof. Augusto B. Federici. Articoli Originali pubblicati su Riviste Certificate PUBMED degli ultimi 20 anni (1998-2018)

1. **Federici AB**, Stabile F, Castaman G, Canciani MT, Mannucci PM. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood. 1998 Oct 15;92(8):2707-11.

2. Di Paola J, **Federici AB**, Mannucci PM, Canciani MT, Kritzik M, Kunicki TJ, Nugent D. Low platelet alpha2beta1 levels in type I von Willebrand disease correlate with impaired platelet function in a high shear stress system. Blood. 1999 Jun 1;93(11):3578-82.

3. **Federici AB**. Therapeutic approaches to acquired von Willebrand syndrome. Expert Opin Investig Drugs. 2000 Feb;9(2):347-54.

4. **Federici AB**, Rand JH, Bucciarelli P, Budde U, van Genderen PJ, Mohri H, Meyer D, Rodeghiero F, Sadler JE. Subcommittee on von Willebrand Factor. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost. 2000 Aug;84(2):345-9. Erratum in: Thromb Haemost 2000 Oct;84(4):739.

5. Baronciani L, Cozzi G, Canciani MT, Peyvandi F, Srivastava A, **Federici AB**, Mannucci PM. Molecular characterization of a multiethnic group of 21 patients with type 3 von Willebrand disease. Thromb Haemost. 2000 Oct;84(4):536-40.

6. **Federici AB**, Rand JH, Mannucci PM. Acquired von Willebrand syndrome: an important bleeding complication to be considered in patients with lymphoproliferative and myeloproliferative disorders. Hematol J. 2001;2(6):358-62.

7. **Federici AB**, Castaman G, Mannucci PM, Italian Association of Hemophilia Centers (AICE). Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia. 2002 Sep;8(5):607-21.

8. Castaman G, **Federici AB**, Rodeghiero F, Mannucci PM. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica. 2003 Jan;88(1):94-108.

9. Federici AB, Mannucci PM. Diagnosis and management of acquired von Willebrand syndrome. Clin Adv Hematol Oncol. 2003 Mar;1(3):169-75.

10. Baronciani L, Cozzi G, Canciani MT, Peyvandi F, Srivastava A, **Federici AB**, Mannucci PM. Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. Blood Cells Mol Dis. 2003 May-Jun;30(3):264-70.

11. **Federici AB**. The factor VIII/von Willebrand factor complex: basic and clinical issues. Haematologica. 2003 Jun;88(6):EREP02.

12. **Federici AB**, Canciani MT, Forza I, Mannucci PM, Marchese P, Ware J, Ruggeri ZM. A sensitive ristocetin co-factor activity assay with recombinant glycoprotein Ibalpha for the diagnosis of patients with low von Willebrand factor levels. Haematologica. 2004 Jan;89(1):77-85.

13. **Federici AB**, Budde U, Rand JH. Acquired von Willebrand syndrome 2004: International Registry--diagnosis and management from online to bedside. Hamostaseologie. 2004 Feb;24(1):50-5.

14. Srámek A, Bucciarelli P, **Federici AB**, Mannucci PM, De Rosa V, Castaman G, Morfini M, Mazzucconi MG, Rocino A, Schiavoni M, Scaraggi FA, Reiber JH, Rosendaal FR. Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation. 2004 Feb 17;109(6):740-4.

15. **Federici AB**, Mazurier C, Berntorp E, Lee CA, Scharrer I, Goudemand J, Lethagen S, Nitu I, Ludwig G, Hilbert L, Mannucci PM. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood. 2004 Mar 15;103(6):2032-8.

16. Kunicki TJ, **Federici AB**, Salomon DR, Koziol JA, Head SR, Mondala TS, Chismar JD, Baronciani L, Canciani MT, Peake IR. An association of candidate gene haplotypes and bleeding severity in von Willebrand disease (VWD) type 1 pedigrees. Blood. 2004 Oct 15;104(8):2359-67.

17. Marchese M, De Cristofaro R, **Federici AB**, Biondi A, Petruzziello L, Tringali A, Spada C, Mutignani M, Ronconi P, Costamagna G. Duodenal and gastric Dieulafoy's lesions in a patient with type 2A von Willebrand's disease. Gastrointest Endosc. 2005 Feb;61(2):322-5.
18. **Federici AB**. Use of intravenous immunoglobulin in patients with acquired von Willebrand syndrome. Hum Immunol. 2005 Apr;66(4):422-30.

19. Goudemand J, Scharrer I, Berntorp E, Lee CA, Borel-Derlon A, Stieltjes N, Caron C, Scherrmann JM, Bridey F, Tellier Z, **Federici AB**, Mannucci PM. Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. J Thromb Haemost. 2005 Oct;3(10):2219-27.

20. Baronciani L, **Federici AB**, Beretta M, Cozzi G, Canciani MT, Mannucci PM.Expression studies on a novel type 2B variant of the von Willebrand factor gene (R1308L) characterized by defective collagen binding. J Thromb Haemost. 2005 Dec;3(12):2689-94.

21. Rodeghiero F, Castaman G, Tosetto A, Batlle J, Baudo F, Cappelletti A, Casana P, De Bosch N, Eikenboom JC, **Federici AB**, Lethagen S, Linari S, Srivastava A. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost. 2005 Dec;3(12):2619-26.

22. **Federici AB**. Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders. Semin Hematol. 2006 Jan;43(1 Suppl 1):S48-58.

23. Kunicki TJ, Baronciani L, Canciani MT, Gianniello F, Head SR, Mondala TS, Salomon DR, **Federici AB**. An association of candidate gene haplotypes and bleeding severity in von Willebrand disease type 2A, 2B, and 2M pedigrees. J Thromb Haemost. 2006 Jan;4(1):137-47.

24. Castaman G, **Federici AB**, Bernardi M, Moroni B, Bertoncello K, Rodeghiero F. Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective studycomparing patients with single (R1205H) and double (R1205H-M740I) defect. J Thromb Haemost. 2006 Feb;4(2):357-60.

25. Tosetto A, Rodeghiero F, Castaman G, Goodeve A, **Federici AB**, Batlle J, Meyer D, Fressinaud E, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost. 2006 Apr;4(4):766-73.

26. Eikenboom J, Van Marion V, Putter H, Goodeve A, Rodeghiero F, Castaman G, **Federici AB**, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost. 2006 Apr;4(4):774-82.

27. **Federici AB**, Santagostino E, Rumi MG, Russo A, Mancuso ME, Soffredini R, Mannucci PM, Colombo M. The natural history of hepatitis C virus infection in Italian patients with von Willebrand's disease: a cohort study.Haematologica. 2006 Apr;91(4):503-8.

28. **Federici AB**, Castaman G, Thompson A, Berntorp E. Von Willebrand's disease: clinical management. Haemophilia. 2006 Jul;12 Suppl 3:152-8.

29. Baronciani L, **Federici AB**, Cozzi G, Canciani MT, Mannucci PM. Von Willebrand factor collagen binding assay in von Willebrand disease type 2A, 2B, and 2M. J Thromb Haemost. 2006 Sep;4(9):2088-90.

30. Ruggeri ZM, Orje JN, Habermann R, **Federici AB**, Reininger AJ. Activation-independent platelet adhesion and aggregation under elevated shear stress. Blood. 2006 Sep 15;108(6):1903-10.

31. Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, **Federici AB**, Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006 Oct;4(10):2103-14.

32. Castaman G, Rodeghiero F, Tosetto A, Cappelletti A, Baudo F, Eikenboom JC, **Federici AB**, Lethagen S, Linari S, Lusher J, Nishino M, Petrini P, Srivastava A, Ungerstedt JS. Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study. J Thromb Haemost. 2006 Oct;4(10):2164-9.

33. De Cristofaro R, Peyvandi F, Baronciani L, Palla R, Lavoretano S, Lombardi R, Di Stasio E, **Federici AB**, Mannucci PM. Molecular mapping of the chloride-binding site in von Willebrand factor (VWF): energetics and conformational effects on the VWF/ADAMTS-13 interaction. J Biol Chem. 2006 Oct 13;281(41):30400-11.

34. Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, **Federici AB**, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Hashemi Soteh M, Baronciani L, Hallden C, Guilliatt A, Lester W, Peake I. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood. 2007 Jan 1;109(1):112-21.

35. Baronciani L, **Federici AB**, Cozzi G, Canciani MT, Mannucci PM. Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease J Thromb Haemost. 2007 Feb;5(2):282-8.

36. Tosetto A, Rodeghiero F, Castaman G, Bernardi M, Bertoncello K, Goodeve A, **Federici AB**, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I.Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD). J Thromb Haemost. 2007 Apr;5(4):715-21.

37. Schneppenheim R, Castaman G, **Federici AB**, Kreuz W, Marschalek R, Oldenburg J, Oyen F, Budde U. A common 253-kb deletion involving VWF and TMEM16B in German and Italian patients with severe von Willebrand disease type 3.J Thromb Haemost. 2007 Apr;5(4):722-8.

38. Borel-Derlon A, **Federici AB**, Roussel-Robert V, Goudemand J, Lee CA, Scharrer I, Rothschild C, Berntorp E, Henriet C, Tellier Z, Bridey F, Mannucci PM. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients.J Thromb Haemost. 2007 Jun;5(6):1115-24.

39. **Federici AB**, Castaman G, Franchini M, Morfini M, Zanon E, Coppola A, Tagliaferri A, Boeri E, Mazzucconi MG, Rossetti G, Mannucci PM. Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients. Haematologica. 2007 Jul;92(7):944-51.

40. **Federici AB**. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO.WILL Study. Haemophilia. 2007 Dec;13 Suppl 5:15-24.

41. **Federici AB**. The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007) Haemophilia. 2008 Jan;14 Suppl 1:5-14.

42. **Federici AB**. Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg? J Thromb Haemost. 2008 Apr;6(4):565-8.

43. Castaman G, Lethagen S, **Federici AB**, Tosetto A, Goodeve A, Budde U, Batlle J, Meyer D, Mazurier C, Fressinaud E, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Pasi J, Hill F, Peake I, Rodeghiero F. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood. 2008 Apr 1;111(7):3531-9.

44. Budde U, Schneppenheim R, Eikenboom J, Goodeve A, Will K, Drewke E, Castaman G, Rodeghiero F, **Federici AB**, Batlle J, Pérez A, Meyer D, Mazurier C, Goudemand J, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost. 2008 May;6(5):762-71.

45. Baronciani L, **Federici AB**, Castaman G, Punzo M, Mannucci PM. Prevalence of type 2b 'Malmö/New York' von Willebrand disease in Italy: the role of von Willebrand factor gene conversion. J Thromb Haemost. 2008 May;6(5):887-90.

46. Baronciani L, **Federici AB**, Cozzi G, La Marca S, Punzo M, Rubini V, Canciani MT, Mannucci PM. Expression studies of missense mutations p.D141Y, p.C275S located in the propeptide of von Willebrand factor in patients with type 3 von Willebrand disease. Haemophilia. 2008 May;14(3):549-55.

47. Franchini M, Gandini G, Giuffrida A, De Gironcoli M, **Federici AB**. Treatment for patients with type 3 von Willebrand disease and alloantibodies: a case report. Haemophilia. 2008 May;14(3):645-6.

48. Haberichter SL, Castaman G, Budde U, Peake I, Goodeve A, Rodeghiero F, **Federici AB**, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill FG, Montgomery RR. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood. 2008 May 15;111(10):4979-85.

49. Collins P, Budde U, Rand JH, **Federici AB**, Kessler CM. Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome. Haemophilia. 2008 Jul;14 Suppl 3:49-55.

50. **Federici AB**. Clinical and molecular markers of inherited von Willebrand disease type 3: are deletions of the VWF gene associated with alloantibodies to VWF? J Thromb Haemost. 2008 Oct;6(10):1726-8.

51. Budde U, **Federici AB**, Goodeve A, Eikenboom J, Schneppenheim R. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD): reply to a rebuttal. J Thromb Haemost. 2008 Nov;6(11):2002-3.

52. **Federici AB**, Mannucci PM, Castaman G, Baronciani L, Bucciarelli P, Canciani MT, Pecci A, Lenting PJ, De Groot PG. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: A cohort study of 67 patients. Blood. 2009 Jan 15;113(3):526-534.

53. **Federici AB**. The safety of plasma-derived von Willebrand/factor VIII concentrates in the management of inherited von Willebrand disease. Expert Opin Drug Saf. 2009 Mar;8(2):203-10.

54. Mannucci PM, Franchini M, Castaman G, **Federici AB**. Italian Association of Hemophilia Centers. Evidence-based recommendations on the treatment of von Willebrand disease in Italy. Blood Transfus. 2009 Apr;7(2):117-26.

55. **Federici AB**, Canciani MT. Clinical and laboratory versus molecular markers for a correct classification of von Willebrand disease. Haematologica. 2009 May;94(5):610-5.

56. Baronciani L, **Federici AB**, Punzo M, Solimando M, Cozzi G, La Marca S, Rubini V, Canciani MT, Mannucci PM. Type 2A (IIH) von Willebrand disease is due to mutations that affect von Willebrand factor multimerization .J Thromb Haemost. 2009 Jul;7(7):1114-22.

57. James AH, Kouides PA, Abdul-Kadir R, Edlund M, **Federici AB**, Halimeh S, Kamphuisen PW, Konkle BA, Martínez-Perez O, McLintock C, Peyvandi F, Winikoff R. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. Am J Obstet Gynecol. 2009 Jul;201(1):12.e1-8.

58. Nurden AT, **Federici AB**, Nurden P.Altered megakaryocytopoiesis in von Willebrand type 2B disease. J Thromb Haemost. 2009 Jul;7 Suppl 1:277-81.

59. Eikenboom J, Hilbert L, Ribba AS, Hommais A, Habart D, Messenger S, Al-Buhairan A, Guilliatt A, Lester W, Mazurier C, Meyer D, Fressinaud E, Budde U, Will K, Schneppenheim R, Obser T, Marggraf O, Eckert E, Castaman G, Rodeghiero F, **Federici AB**, Batlle J, Goudemand J, Ingerslev J, Lethagen S, Hill F, Peake I, Goodeve A. Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study. J Thromb Haemost. 2009 Aug;7(8):1304-12.

60. Mannucci PM, **Federici AB**, James AH, Kessler CM. von Willebrand disease in the 21st century: current approaches and new challenges. Haemophilia. 2009 Sep;15(5):1154-8.

61. Nurden P, Nurden AT, La Marca S, Punzo M, Baronciani L, **Federici AB**. Platelet morphological changes in two patients with von Willebrand disease type 3 caused by large homozygous deletions of the von Willebrand factor gene. Haematologica. 2009 Nov;94(11):1627-9.

62. **Federici AB**. Classification of inherited von Willebrand disease and implications in clinical practice.Thromb Res. 2009 Nov;124 Suppl 1:S2-6.

63. Kouides P, **Federici AB**, James AH, Berntorp E, Abshire T, Kreuz W. Diagnosis and management of inherited von Willebrand disease in the next decade: panel discussion. Thromb Res. 2009 Nov;124 Suppl 1:S20-1.

64. Siboni SM, Spreafico M, Calò L, Maino A, Santagostino E, **Federici AB**, Peyvandi F. Gynaecological and obstetrical problems in women with different bleeding disorders. Haemophilia. 2009 Nov;15(6):1291-9.

65. Platè M, Duga S, Baronciani L, La Marca S, Rubini V, Mannucci PM, **Federici AB**, Asselta R. Premature termination codon mutations in the Von Willebrand factor gene are associated with allele-specific and position-dependent mRNA decay. Haematologica. 2010 Jan;95(1):172-4.

66. **Federici AB**, Barillari G, Zanon E, Mazzucconi MG, Musso R, Targhetta R, Mannucci PM. Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand's disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score. Haemophilia. 2010 Jan;16(1):101-10.

67. Baronciani L, Peyvandi F, Punzo M, Lancellotti S, Canciani MT, **Federici AB**, De Cristofaro R. Relevance of chloride binding to von Willebrand factor in type 2B von Willebrand disease patients.J Thromb Haemost. 2010 Feb;8(2):416-8.

68. Nurden P, Gobbi G, Nurden A, Enouf J, Youlyouz-Marfak I, Carubbi C, La Marca S, Punzo M, Baronciani L, De Marco L, Vitale M, **Federici AB**. Abnormal VWF modifies megakaryocytopoiesis: studies of platelets and megakaryocyte cultures from von Willebrand disease type 2B patients. Blood. 2010 Apr 1;115(13):2649-56.

69. Castaman G, Tosetto A, Cappelletti A, Goodeve A, **Federici AB**, Batlle J, Meyer D, Goudemand J, Eikenboom JC, Schneppenheim R, Budde U, Ingerslev J, Lethagen S, Hill F, Peake IR, Rodeghiero F. Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD. Thromb Res. 2010 Sep;126(3):227-31.

70. Hickson N, Hampshire D, Winship P, Goudemand J, Schneppenheim R, Budde U, Castaman G, Rodeghiero F, **Federici AB**, James P, Peake I, Eikenboom J, Goodeve A; on behalf of the MCMDM-1VWD and ZPMCB-VWD study groups. von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels J Thromb Haemost. 2010 Sep;8(9):1986-93.

71. Castaman G, Tosetto A, Goodeve A, **Federici AB**, Lethagen S, Budde U, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Habart D, Hill F, Peake I, Rodeghiero F. The impact of bleeding history, von Willebrand factor and PFA-100 on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM-1VWD. Br J Haematol. 2010 Nov;151(3):245-51.

72. Lee CA, Hubbard A, Sabin CA, Budde U, Castaman G, J Favaloro E, Friedman KD, **Federici AB**, on behalf of the ISTH-SSC sub-committee on VWF. Laboratory diagnosis of von Willebrand disease: results from a prospective and blind study in 32 laboratories worldwide using lyophilized plasmas. J Thromb Haemost. 2011 Jan;9(1):220-2.

73. Pecori Giraldi F, Ambrogio AG, Fatti LM, Rubini V, Cozzi G, Scacchi M, **Federici AB**, Cavagnini F. Von Willebrand factor and fibrinolytic parameters during the desmopressin test in patients with Cushing's disease. Br J Clin Pharmacol. 2011 Jan;71(1):132-6.

74. Tosetto A, Rodeghiero F, Castaman G, Goodeve A, **Federici AB**, Batlle J, Meyer D, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Lethagen S, Hill FG, Peake I. A comparison between two semi-quantitative bleeding scales for the diagnosis and assessment of bleeding severity in type 1 von Willebrand disease.Haemophilia. 2011 Jan;17(1):165-6.

75. **Federici AB**. Acquired von Willebrand syndrome associated with hypothyroidism: a mild bleeding disorder to be further investigated. Semin Thromb Hemost. 2011 Feb;37(1):35-40.

76. Castaman G, Tosetto A, **Federici AB**, Rodeghiero F. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance. Thromb Haemost. 2011 Apr;105(4):647-54.

77. Giannini S, Solimando M, Fierro T, Baronciani L, **Federici AB**, Gresele P. Acquired von Willebrand syndrome type 2A in a JAK2-positive essential thrombocythaemia-affected member of a large von Willebrand disease family with a novel autosomal dominant A1716P mutation. Thromb Haemost. 2011 May;105(5):921-4.

78. **Federici AB**. The von Willebrand factor from basic mechanisms to clinical practice. Blood Transfus. 2011 May;9 Suppl 2:s1-2. doi: 10.2450/2011.001S.

79. Tiede A, Rand JH, Budde U, Ganser A, **Federici AB**. How I treat the acquired von Willebrand syndrome. Blood. 2011 Jun 23;117(25):6777-85.

80. **Federici AB**, Bucciarelli P, Castaman G, Baronciani L, Canciani MT, Mazzucconi MG, Morfini M, Rocino A, Schiavoni M, Oliovecchio E, Iorio A, Mannucci PM. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients. Semin Thromb Hemost. 2011 Jul;37(5):511-21.

81. Gritti G, Cortelezzi A, Bucciarelli P, Rezzonico F, Lonati S, La Marca S, Silvestris I, **Federici AB**. Circulating and progenitor endothelial cells are abnormal in patients with different types of von Willebrand disease and correlate with markers of angiogenesis. Am J Hematol. 2011 Aug;86(8):650-6.

82. James AH, Kouides PA, Abdul-Kadir R, Dietrich JE, Edlund M, **Federici AB**, Halimeh S, Kamphuisen PW, Lee CA, Martínez-Perez O, McLintock C, Peyvandi F, Philipp C, Wilkinson J, Winikoff R. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol. 2011 Oct;158(2):124-34.

83. Nisar S, Daly ME, **Federici AB**, Artoni A, Mumford AD, Watson SP, Mundell SJ. An intact PDZ-motif is essential for correct P2Y12 purinoceptor traffic in human platelets. Blood. 2011 Nov 17;118(20):5641-51.

84. **Federici AB**, Rossi V, Sacchi E, Franchini M. Are intravenous immunoglobulins really inappropriate in acquired von Willebrand syndrome? Blood Transfus. 2012 Jul;10(3):402-3.

85. Castaman G, **Federici AB**, Tosetto A, La Marca S, Stufano F, Mannucci PM, Rodeghiero F. Different bleeding risk in type 2 A and 2 M Von Willebrand disease: a two-year prospective study in 107 patients. J Thromb Haemost. 2012 Apr;10(4):632-8.

86. Castaman G, Baronciani M, Canciani MT, **Federici AB**. Different bleeding risk in type 2 A and 2 M von Willebrand disease: a 2-year prospective study in 107 patients: a reply to a rebuttal J Thromb Haemost. 2012 Jul;10(7):1458-60.

87. **Federici AB**, James P. Current management of patients with severe von Willebrand disease type 3: a 2012 update. Acta Haematol. 2012;128(2):88-99.

88. Solimando M, Baronciani L, La Marca S, Cozzi G, Asselta R, Canciani MT, **Federici AB**, Peyvandi F. Molecular characterization, recombinant protein expression, and mRNA analysis of type 3 von Willebrand disease: Studies of an Italian cohort of 10 patients. Am J Hematol. 2012 Sep;87(9):870-4.

89. Abshire TC, **Federici AB**, Alvárez MT, Bowen J, Carcao MD, Cox Gill J, Key NS, Kouides PA, Kurnik K, Lail AE, Leebeek FW, Makris M, Mannucci PM, Winikoff R, Berntorp E, VWD PN. Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). Haemophilia. 2013 Jan;19(1):76-81.

90. Castaman G, Coppola A, Zanon E, Boeri E, Musso M, Siragusa S, **Federici AB**, Mancuso G, Barillari G, Biasoli C, Feola G, Franchini M, Moratelli S, Gamba G, Schinco P, Valdrè L, Dragani A, Mazzucconi G, Tagliaferri A, Morfini M. Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease. Haemophilia. 2013 Jan;19(1):82-8.

91. **Federici AB**, Budde U, Castaman G, Rand JH, Tiede A. Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. Semin Thromb Hemost. 2013 Mar;39(2):191-201.

92. Eikenboom J, **Federici AB**, Dirven RJ, Castaman G, Rodeghiero F, Budde U, Schneppenheim R, Batlle J, Canciani MT, Goudemand J, Peake I, Goodeve A; MCMDM-1VWD Study Group. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. Blood. 2013 Mar 21;121(12):2336-9.

93. Pecori Giraldi F, **Federici AB**, Cavagnini F. Caution during use of desmopressin in IPSS. J Neurointerv Surg. 2013 Sep 1;5(5):e27.

94. Callaghan MU, Wong TE, **Federici AB**. Treatment of acquired von Willebrand syndrome in childhood. Blood. 2013 Sep 19;122(12):2019-22.

95. Kadir RA, Davies J, Winikoff R, Pollard D, Peyvandi F, Garagiola I, Pabinger I, **Federici AB**. Pregnancy complications and obstetric care in women with inherited bleeding disorders. Haemophilia. 2013 Nov;19 Suppl 4:1-10.

96. **Federici AB**, Intini D, Lattuada A, Vanelli C, Arrigoni L, Sacchi E, Russo U. Supportive transfusion therapy in cancer patients with acquired defects of hemostasis. Thromb Res. 2014 May;133 Suppl 2:S56-62.

97. **Federici AB**, Bucciarelli P, Castaman G, Mazzucconi MG, Morfini M, Rocino A, Schiavoni M, Peyvandi F, Rodeghiero F, Mannucci PM. The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. Blood. 2014 Jun 26;123(26):4037-44.

98. Abdul-Kadir R, McLintock C, Ducloy AS, El-Refaey H, England A, **Federici AB**, Grotegut CA, Halimeh S, Herman JH, Hofer S, James AH, Kouides PA, Paidas MJ, Peyvandi F, Winikoff R. Evaluation and management of postpartum hemorrhage: consensus from an international expert panel. Transfusion. 2014 Jul;54(7):1756-68.

99. Makris M, **Federici AB**, Mannucci PM, Bolton-Maggs PH, Yee TT, Abshire T, Berntorp E.The natural history of occult or angiodysplastic gastrointestinal bleeding in von Willebrand disease. Haemophilia. 2014.

100. **Federici AB**. Clinical and laboratory diagnosis of VWD. Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):524-30.

101. Makris M, **Federici AB**, Mannucci PM, Bolton-Maggs PH, Yee TT, Abshire T, Berntorp E. The natural history of occult or angiodysplastic gastrointestinal bleeding in von Willebrand disease. Haemophilia. 2015 May;21(3):338-42.

102. Holm E, Abshire TC, Bowen J, Álvarez MT, Bolton-Maggs P, Carcao M, **Federici AB**, Gill JC, Halimeh S, Kempton C, Key NS, Kouides P, Lail A, Landorph A, Leebeek F, Makris M, Mannucci P, Mauser-Bunschoten EP, Nugent D, Valentino LA, Winikoff R, Berntorp E. Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network. Blood Coagul Fibrinolysis. 2015 Jun;26(4):383-8.

103. Bodó I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J, von Willebrand factor Subcommittee of the Standardization and Scientific Committee of the International Society for Thrombosis and Haemostasis. Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. J Thromb Haemost. 2015 Jul;13(7):1345-50.

104. **Federici AB**. Prophylaxis in patients with von Willebrand disease: who, when, how? J Thromb Haemost. 2015 Sep;13(9):1581-4.

105. **Federici AB**. HDL/ApoA-I: role in VWF-dependent thrombosis. Blood. 2016 Feb 4;127(5):526-8.

106. **Federici AB**. Towards a more automatic and rapid laboratory diagnosis of von Willebrand disease. Thromb Res. 2016 May;141:198-201.

107. **Federici AB**. Current and emerging approaches for assessing von Willebrand disease in 2016. Int J Lab Hematol. 2016 May;38 Suppl 1:41-9.

108. Castaman G, **Federici AB**. Type 2B von Willebrand Disease: A Matter of Plasma Plus Platelet Abnormality. Semin Thromb Hemost. 2016 Jul;42(5):478-82.

109. James AH, Eikenboom J, **Federici AB**. State of the art: von Willebrand disease. Haemophilia. 2016 Jul;22 Suppl 5:54-9.

110. **Federici AB**, Königs C, James AH. Contemporary issues in the management of von Willebrand disease. Thromb Haemost. 2016 Aug 31;116 Suppl 1:S18-25.

111. Tagariello G, Castaman G, Falanga A, Santoro R, Napolitano M, Storti S, Veneri D, Basso M, Candiotto L, Tassinari C, Federici AB, De Stefano V, GIMEMA Haemostasis and Thrombosis working party. Italian daily platelet transfusion practice for haematological patients undergoing high dose chemotherapy with or without stem cell transplantation: a survey by the GIMEMA Haemostasis and Thrombosis Working Party. Blood Transfus. 2016 Nov;14(6):521-526.

112. Mannucci PM, Peyvandi F, Federici AB, Ciavarella N. 9th BIC International Conference: Rome (Italy), 15-17 September 2017. Blood Transfus. 2017 Sep 12;15(Supplement no. 3):s475-s518.

113. Berntorp E, Ågren A, Aledort L, Blombäck M, Cnossen MH, Croteau SE, von Depka M, **Federici AB**, Goodeve A, Goudemand J, Mannucci PM, Mourik M, Önundarson PT, Rodeghiero F, Szántó T, Windyga J. Fifth Åland Island conference on von Willebrand disease. Haemophilia. 2018 May;24 Suppl 4:5-19.

114. Schinco P, Castaman G, Coppola A, Cultrera D, Ettorre C, Giuffrida AC, Marchesini E, Marino R, Milan M, Molinari C, Siboni SM, Zanon E, **Federici AB**. Current challenges in the diagnosis and management of patients with inherited von Willebrand's disease in Italy: an Expert Meeting Report on the diagnosis and surgical and secondary long-term prophylaxis. Blood Transfus. 2018 Jul;16(4):371-381.

115. Pasca S, Ambaglio C, Rocino A, Santoro C, Cantori I, Zanon E, FAIR Study Group. Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired haemophilia A: data from FAIR Registry. J Thromb Thrombolysis. 2019 Jan;47(1):129-133.

116. Peyvandi F, Castaman G, Gresele P, De Cristofaro R, Schinco P, Bertomoro A, Morfini M, Gamba G, Barillari G, Jiménez-Yuste V, Königs C, Iorio A, **Federici AB**. A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease. Blood Transfus. 2019 Feb 4:1-8. doi: 10.2450/2019.0183-18. [Epub ahead of print]

117. Zanon E, Pasca S, Santoro C, Gamba G, Siragusa SM, Rocino A, Cantori I, **Federici AB**, Mameli L, Giuffrida G, Falanga A, Lodigiani C, Santoro RC, Milan M, Ambaglio C, Napolitano M, Mazzucconi MG. Activated prothrombin complex concentrate (FEIBA®) in acquired haemophilia A: a large multicentre Italian study - the FAIR Registry. Br J Haematol. 2019 Mar;184(5):853-855.

118. Napolitano M, Saccullo G, Marietta M, Carpenedo M, Castaman G, Cerchiara E, Chistolini A, Contino L, De Stefano V, Falanga A, **Federici AB**, Rossi E, Santoro R, Siragusa S; Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Working Party on Thrombosis and Hemostasis; Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Working Party on Thrombosis and Haemostasis (see Appendix 1), De Stefano V, Falanga A, Tosetto A, Avvisati G, Carpenedo M, Federici AB, Marietta M, Napolitano M, Rossi E, Santoro C, Castaman G, Cerchiara E, Chistolini A, Contino L, Mazzucconi MG, Nichele I, Russo L, Santi R, Santoro RC, Siragusa S, Tagariello G.
Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus.
Blood Transfus. 2019 May;17(3):171-180.

119. Peyvandi F, Castaman G, Gresele P, De Cristofaro R, Schinco P, Bertomoro A, Morfini M, Gamba G, Barillari G, Jiménez-Yuste V, Königs C, Iorio A, **Federici AB**.
A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.
Blood Transfus. 2019 Feb 4:1-8. doi: 10.2450/2019.0183-18. [Epub ahead of print]

Si autorizza al trattamento dei dati personali

Firmato in data 28 Agosto 2019